Cancer Genetics’ Proprietary IVD for Cervical Cancer, FHACT®, Receives CE Mark

By Italia on September 2 2014

> CE marking allows CGI’s DNA-FISH Probe, FHACT®, to be widely marketed in European Economic Area, which covers 31 countries RUTHERFORD, N.J., September 02, 2014 – Cancer Genetics, Inc. (Nasdaq; CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT®) has received the CE […]

Continue Reading